Balyasny Asset Management’s Viking Therapeutics VKTX Stock Holding History

Balyasny Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,400	Closed	-$260K	–	3585
2025 Q4	$260K	Sell	7,400 -200,000	-96%	-$7.09M	﹤0.01%	2787
2025 Q3	$5.45M	Sell	207,400 -2,163,900	-91%	-$64.6M	0.01%	1334
2025 Q2	$62.8M	Sell	2,371,300 -567,500	-19%	-$14.9M	0.09%	257
2025 Q1	$71M	Buy	2,938,800 +2,481,400	+543%	+$78.4M	0.12%	201
2024 Q4	$18.4M	Buy	457,400 +429,800	+1,557%	+$24.5M	0.03%	703
2024 Q3	$1.75M	Sell	27,600 -29,800	-52%	-$1.75M	﹤0.01%	1729
2024 Q2	$3.04M	Buy	+57,400	New	+$3.76M	0.01%	1381
2024 Q1	–	Sell	-125,000	Closed	-$2.33M	–	3157
2023 Q4	$2.33M	Sell	125,000 -915,000	-88%	-$12M	﹤0.01%	1404
2023 Q3	$11.5M	Buy	+1,040,000	New	+$14.9M	0.02%	792

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Balyasny Asset Management's VKTX Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 36,493 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #2011 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in VKTX as recently as Q1 2025.

Balyasny Asset Management first reported a position in VKTX in Q2 2018 and has held it in 19 quarters since. The position peaked at $41.8M in Q4 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Balyasny Asset Management held 36,493 shares of Viking Therapeutics worth $1.19M as of Q1 2026.
Viking Therapeutics was a new Balyasny Asset Management position in Q1 2026.
Viking Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2011 holding.
Balyasny Asset Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 19 quarters since.
Balyasny Asset Management's Viking Therapeutics position peaked at $41.8M in Q4 2023.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.